A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Interferon-alpha
  • Interleukin-2
  • Kidney Neoplasms
  • Medroxyprogesterone

abstract

  • Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity. Newly available angiogenesis inhibitors should be preferred for these patients.

publication date

  • December 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23056

PubMed ID

  • 17932908

Additional Document Info

start page

  • 2468

end page

  • 77

volume

  • 110

number

  • 11